Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Harrow in a research note issued on Wednesday, August 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.26. The consensus estimate for Harrow's current full-year earnings is $0.30 per share. HC Wainwright also issued estimates for Harrow's FY2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.12) EPS and FY2027 earnings at $0.88 EPS.
Other equities research analysts have also issued reports about the stock. Zacks Research lowered shares of Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday. Wall Street Zen cut Harrow from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Weiss Ratings restated a "sell (e+)" rating on shares of Harrow in a research note on Monday, July 20th. Cantor Fitzgerald lowered their target price on shares of Harrow from $91.00 to $88.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. Finally, BTIG Research reiterated a "buy" rating and issued a $63.00 price target on shares of Harrow in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $69.43.
Read Our Latest Report on HROW
Harrow Stock Down 1.2%
HROW stock opened at $38.87 on Friday. The stock has a market cap of $1.46 billion, a P/E ratio of -38.87 and a beta of 0.28. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. Harrow has a twelve month low of $28.54 and a twelve month high of $54.85. The company's 50 day moving average is $40.81 and its two-hundred day moving average is $39.88.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.28). The business had revenue of $70.66 million during the quarter, compared to analysts' expectations of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 31.83%.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. acquired a new position in Harrow in the 4th quarter worth approximately $26,000. KBC Group NV acquired a new position in Harrow in the 1st quarter worth about $31,000. Raymond James Financial Inc. bought a new stake in shares of Harrow in the 2nd quarter valued at approximately $48,000. SBI Securities Co. Ltd. increased its holdings in Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company's stock worth $52,000 after buying an additional 846 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Harrow during the 2nd quarter worth about $72,000. Institutional investors own 72.76% of the company's stock.
Insider Buying and Selling at Harrow
In other Harrow news, Director Adrienne L. Graves acquired 1,000 shares of Harrow stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at approximately $31,070. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.80% of the stock is currently owned by company insiders.
Key Stories Impacting Harrow
Here are the key news stories impacting Harrow this week:
- Positive Sentiment: HC Wainwright reaffirmed its longer-term outlook for Harrow by projecting $1.07 in fourth-quarter 2027 EPS, slightly above its previous $1.06 estimate. The firm also expects Harrow to reach $0.88 in full-year 2027 EPS, despite lowering that estimate from $1.14. HC Wainwright estimates
- Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter performance as a potential turnaround and rated the shares a cautious buy, suggesting that improving operations could support future growth. Harrow: The Q2 Turnaround Is Enough For A Cautious Buy
- Positive Sentiment: BTIG Research reaffirmed its Buy rating, while coverage highlighted Harrow’s new eye-care product launch and acquisition as potential sources of additional growth. BTIG Research Reaffirms Buy Rating
- Neutral Sentiment: Viatris’ planned sale of Tyrvaya could create an opportunity for Harrow to expand the product into a larger growth engine, though the investment case depends on execution and commercial adoption. Tyrvaya growth opportunity
- Negative Sentiment: HC Wainwright sharply reduced its forecasts: FY2026 EPS moved from $0.15 to a loss of $0.57, Q3 2026 EPS from $0.26 to $0.01, Q1 2027 EPS from a $0.43 loss to a $0.63 loss, and Q2 2027 EPS from a $0.03 loss to a $0.12 loss. Zacks Research also downgraded Harrow from “Hold” to “Strong Sell.” Zacks downgrade
- Negative Sentiment: The stock gapped down following quarterly results in which Harrow reported a $0.46 per-share loss, missing the $0.18 consensus estimate, although revenue of $70.66 million modestly exceeded expectations. Harrow shares gap down following weak earnings
About Harrow
(
Get Free Report)
Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
